362 related articles for article (PubMed ID: 25955301)
41. Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma.
Wei BR; Hoover SB; Peer CJ; Dwyer JE; Adissu HA; Shankarappa P; Yang H; Lee M; Peat TJ; Figg WD; Simpson RM
Mol Cancer Ther; 2020 Nov; 19(11):2308-2318. PubMed ID: 32943547
[TBL] [Abstract][Full Text] [Related]
42. Combined inhibition of MEK and mammalian target of rapamycin abolishes phosphorylation of cyclin-dependent kinase 4 in glioblastoma cell lines and prevents their proliferation.
Paternot S; Roger PP
Cancer Res; 2009 Jun; 69(11):4577-81. PubMed ID: 19458076
[TBL] [Abstract][Full Text] [Related]
43. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition.
Deng W; Gopal YN; Scott A; Chen G; Woodman SE; Davies MA
Pigment Cell Melanoma Res; 2012 Mar; 25(2):248-58. PubMed ID: 22171948
[TBL] [Abstract][Full Text] [Related]
44. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
45. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.
Gao MZ; Wang HB; Chen XL; Cao WT; Fu L; Li Y; Quan HT; Xie CY; Lou LG
Acta Pharmacol Sin; 2019 Feb; 40(2):268-278. PubMed ID: 29777202
[TBL] [Abstract][Full Text] [Related]
46. A novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor.
Ishida N; Fukazawa T; Maeda Y; Yamatsuji T; Kato K; Matsumoto K; Shimo T; Takigawa N; Whitsett JA; Naomoto Y
Exp Cell Res; 2015 Jul; 335(2):197-206. PubMed ID: 25839409
[TBL] [Abstract][Full Text] [Related]
47. Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK.
Tran KB; Kolekar S; Jabed A; Jaynes P; Shih JH; Wang Q; Flanagan JU; Rewcastle GW; Baguley BC; Shepherd PR
BMC Cancer; 2021 Feb; 21(1):136. PubMed ID: 33549048
[TBL] [Abstract][Full Text] [Related]
48. BRAF and MEK inhibition in melanoma.
Dossett LA; Kudchadkar RR; Zager JS
Expert Opin Drug Saf; 2015 Apr; 14(4):559-70. PubMed ID: 25648338
[TBL] [Abstract][Full Text] [Related]
49. Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells.
Margue C; Philippidou D; Kozar I; Cesi G; Felten P; Kulms D; Letellier E; Haan C; Kreis S
J Exp Clin Cancer Res; 2019 Feb; 38(1):56. PubMed ID: 30728057
[TBL] [Abstract][Full Text] [Related]
50. Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells.
Molnár E; Rittler D; Baranyi M; Grusch M; Berger W; Döme B; Tóvári J; Aigner C; Tímár J; Garay T; Hegedűs B
BMC Cancer; 2018 May; 18(1):542. PubMed ID: 29739364
[TBL] [Abstract][Full Text] [Related]
51. Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function.
Manzini C; Venè R; Cossu I; Gualco M; Zupo S; Dono M; Spagnolo F; Queirolo P; Moretta L; Mingari MC; Pietra G
Oncotarget; 2016 Sep; 7(38):60858-60871. PubMed ID: 27563819
[TBL] [Abstract][Full Text] [Related]
52. PDK1 is a potential therapeutic target against angiosarcoma cells.
Wada M; Horinaka M; Yasuda S; Masuzawa M; Sakai T; Katoh N
J Dermatol Sci; 2015 Apr; 78(1):44-50. PubMed ID: 25726712
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
54. Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas.
Inaba K; Oda K; Ikeda Y; Sone K; Miyasaka A; Kashiyama T; Fukuda T; Uehara Y; Arimoto T; Kuramoto H; Wada-Hiraike O; Kawana K; Yano T; Osuga Y; Fujii T
Gynecol Oncol; 2015 Aug; 138(2):323-31. PubMed ID: 26033306
[TBL] [Abstract][Full Text] [Related]
55. Antiproliferative effects of rapamycin and celecoxib in angiosarcoma cell lines.
Bundscherer A; Vogt T; Köhl G; Landthaler M; Hafner C
Anticancer Res; 2010 Oct; 30(10):4017-23. PubMed ID: 21036716
[TBL] [Abstract][Full Text] [Related]
56. Clinical Development of BRAF plus MEK Inhibitor Combinations.
Subbiah V; Baik C; Kirkwood JM
Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454
[TBL] [Abstract][Full Text] [Related]
57. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
58. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
59. EGFR targeting monoclonal antibody combines with an mTOR inhibitor and potentiates tumor inhibition by acting on complementary signaling hubs.
James R; Vishwakarma S; Chivukula IV; Basavaraj C; Melarkode R; Montero E; Nair P
Cancer Med; 2012 Oct; 1(2):114-27. PubMed ID: 23342262
[TBL] [Abstract][Full Text] [Related]
60. Effects of MEK inhibitors GSK1120212 and PD0325901 in vivo using 10-plex quantitative proteomics and phosphoproteomics.
Paulo JA; McAllister FE; Everley RA; Beausoleil SA; Banks AS; Gygi SP
Proteomics; 2015 Jan; 15(2-3):462-73. PubMed ID: 25195567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
